ReviewFuture medicinal chemistry2025
The current landscape of indole hybrids with
Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging Indole and Azaindole Hybrid Agents for Leukemia Therapy: Recent Research Advances and Therapeutic Potential.Archiv der Pharmazie · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer has emerged as a major cause of death throughout the world, leading to around 10 million deaths annually. Anticancer therapeutics play a pivotal role in cancer therapy, but they fail to fully meet the escalating, diverse, and critical needs of patients, underscoring the urgent need for innovative anticancer chemotherapeutics. Indole hybrids can simultaneously modulate multiple targets within cancer cells, potentially addressing drug resistance and adverse events associated with single-component therapies while enhancing therapeutic efficacy and improving pharmacokinetic properties. Diverse indole hybrids, including indole-azoles, indole-chalcones, indole-sulfonamides, indole-sulfones, indole-ureas, and indole-hydrazides, have been designed, synthesized, and evaluated for their
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.